Navigation Links
Angioplasty Reduces Long-term Cardiac Risk in Heart Patients With 'silent' Ischemia

When compared with intensive drug therapy, percutaneous coronary intervention (PCI, angioplasty) was more beneficial in reducing the long-term risk of major cardiac events among heart attack survivors with 'silent ischemia', according to a study.

Cardiac ischemia is caused by insufficient blood flow to the heart muscle tissue. Silent ischemia can occur without accompanying signs or symptoms of angina (chest pain due to inadequate supply of oxygen to the heart muscle), but can be detected by electrocardiogram (ECG) and other techniques.

Silent ischemia has been shown to predict adverse prognosis in patients after myocardial infarction (MI, heart attack), coronary artery bypass graft surgery, and PCI, with or without stenting, according to background information in the article. However, the effect of PCI on the long-term prognosis of patients with silent ischemia after a heart attack is not known.

Paul Erne, M.D., of the Division of Cardiology, Kantonsspital Luzern, Luzern, Switzerland, and colleagues conducted a randomized, unblinded, controlled trial from May 2, 1991, to February 25, 1997, to determine whether PCI compared with drug therapy improves long-term outcome of asymptomatic patients with silent ischemia after a heart attack.

A total of 201 patients with a recent heart attack, silent myocardial ischemia verified by stress imaging, and one- or two-vessel coronary artery disease took part in the study. Ninety-six patients underwent PCI, and 105 patients received intensive anti-ischemic drug therapy. All patients received 100 mg. per day of aspirin and a statin (cholesterol-lowering) drug. Follow-up ended on May 23, 2006.

Patients in the PCI group experienced 27 major adverse cardiac events during an average follow-up of 10.2 years. During the same period, 67 adverse cardiac events occurred in the anti-ischemic drug group. This corresponds to an absolute event reduction of 6.3 percent per ye ar. The rate of ischemia among patients in the PCI group was 11.6 percent at the final follow-up, compared with 28.9 percent among patients in the drug therapy group, despite fewer drugs.

'We found a persistent benefit of PCI compared with optimized drug therapy,' the authors report. 'This benefit became apparent only after two years of observation, with survival curves continuously diverging up to the final follow-up after ten years.'

'This is the first, to our knowledge, long-term outcome study of an invasive therapy compared with an intensive anti-ischemic drug therapy in asymptomatic patients with silent ischemia after a recent MI,' the authors write.

'Our findings argue for an ischemic-targeted approach to PCI among asymptomatic survivors of MI,' they conclude.


'"/>




Related medicine news :

1. Cholesterol Drug Helps After Angioplasty
2. Angioplasty Should be the Standard
3. The Success Rate Of Angioplasty In Female Patients Low
4. Angioplasty The Much Preferred Treatment Of Choice For Heart Attacks
5. Angioplasty death risk reduced by doubling drug dose
6. Angioplasty death risk reduced by doubling drug dose
7. A ray of hope in Angioplasty dilemma
8. Angioplasty plus stenting better than thrombolysis for elderly patients with AMI
9. Patients Fare Better With Doctors Who Do More Angioplasty Procedures
10. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
11. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
Breaking Medicine Technology: